Nifedipine, an L-type calcium (Ca) channel blocker, is one of the most widely used Ca channel-blocking medications for hypertension. Previous studies have reported an association of nifedipine hypertensive treatment with decreased body weight in obese hypertensive humans and rat models. However, the precise mechanism underlying how nifedipine functions metabolically has not been elucidated. Here, we investigated the long-term effect of a non-hypotensive nifedipine dose using a mildly obese, endothelial NO synthase-deficient mouse model. Treating these mice with nifedipine decreased their body weight gain ratio, and white adipose tissue weight compared with the untreated controls. Metabolic analyses indicated that nifedipine treatment upregulated whole-body energy expenditure through increasing oxygen consumption and reducing the respiratory exchange ratio, suggesting that nifedipine promotes lipid oxidation rather than carbohydrate utilization. Furthermore, nifedipine treatment upregulated the expression of the peroxisome proliferator-activated receptor-c coactivator -1a (PGC-1a) in skeletal muscle. Overall, these results suggest that a non-hypotensive dose of nifedipine has pleiotropic effects on energy expenditure that could ameliorate obesity.
INTRODUCTION
Obesity, the most prevalent nutritional disorder in industrialized countries, is a challenging medical problem associated with increased risks of hypertension, cardiovascular disease, hyperlipidemia, diabetes and mortality. Obesity is defined as excess body fat accumulation and results from a daily energy imbalance, such as excess calorie intake and/ or decreased energy consumption. Thus, restoring energy expenditure is considered as an efficient strategy for preventing or treating obesity.
Skeletal muscle is a massive organ accounting for 40-50% of the total body mass and thus significantly expends whole-body energy expenditure even under sedentary conditions. In particular, lipid oxidation in skeletal muscle is critical and has received increased attention for its role in obesity. Specifically, in obese subjects, skeletal muscle has been described to reduce lipid oxidation. 1 A decreased ability to oxidize lipids has been linked with weight gain as well as a propensity towards obesity. Thus, developing effective treatments that can reverse and/or compensate for impaired lipid oxidation in the skeletal muscle of obese subjects is important.
Calcium (Ca) channel blockers are commonly used to treat patients with hypertension. Nifedipine, a widely used antihypertensive drug, is thought to act mainly by blocking dihydropyridine receptor/L-type Ca channels on vascular smooth muscle cells. Nifedipine treatment reduces atherosclerotic plaques in cholesterol-fed rabbits, 2, 3 and suppresses development and progression of atherosclerosis in hypertensive patients. 4, 5 Nifedipine has recently been reported to have pleiotropic effects on endothelial cells, 6, 7 cardiac muscle cells, 8, 9 mesangial cells [10] [11] [12] and neurons, 13, 14 through mechanisms independent of blocking Ca channels. Previous studies have reported that nifedipine treatment decreases body weight in obese hypertensive humans 15 and rat models. 16 These data suggest that antihypertensive doses of nifedipine alter fat metabolism associated with anti-obesity. Interestingly, Iwai et al. 17 recently reported that a non-hypotensive dose of nifedipine decreased the weight of white adipose tissue (WAT) and enhanced insulin sensitivity in obese diabetic KK-A y mice, suggesting that such treatment directly impacts fat metabolism. Nonetheless, the mechanism through which nifedipine treatment modulates energy expenditure has not been fully elucidated.
In this study, we examined the long-term effect of a non-hypotensive dose of nifedipine on mildly obese model mice in which endothelial NO synthase (eNOS) was deficient. Nifedipine treatment antagonized weight gain, and increased whole-body energy expenditure and lipid oxidation in skeletal muscle. Interestingly, we also observed an increase in peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) expression in skeletal muscle of nifedipine-treated eNOS-deficient mice. These results indicate that nifedipine pleiotropically increases energy expenditure and could thereby counteract obesity.
METHODS Animals
All experimental protocols were approved by the Kumamoto University Ethics Review Committee for Animal Experimentation. Male eNOS-deficient mice on a C57BL/6N background were used for all experiments. All animals were bred in a mouse house with automatically controlled lighting (12 h on, 12 h off), and a stable temperature of 231C was maintained throughout. Mice were fed a normal diet (CE-2, CLEA, Tokyo, Japan).
Nifedipine treatment
Mice were divided into two groups (10 per group) and implanted with a mini-osmotic pump (Alzet Corp. Mini-osmotic pump, Model 2002, Palo Alto, CA, USA) in subcutaneous back tissue. Control mice were administrated a vehicle solution (polyethylene glycol 400 (WAKO, Osaka, Japan), ethanol and H 2 O in the ratio 15:15:70). Nifedipine was administered at doses of 1 mg kg À1 per day in the vehicle solution (Bayer Yakuhin, Ltd, Osaka, Japan).
Metabolic measurements
Mice were subjected to metabolic analysis after 16 weeks of administration of either nifedipine or control vehicle. Insulin and glucose tolerance tests (ITT and GTT, respectively) were performed as previously described. 18 For ITT, mice were administered 1.0 U kg À1 of human insulin by intraperitoneal injection. For GTT, mice were deprived of food for 16 h and were injected with glucose intraperitoneally at 1.25 g kg À1 . Serum glucose was measured using the glucose oxidase method (Sanwa Kagaku, Nagoya, Japan), and serum insulin was measured using an insulin immunoassay (Morinaga, Yokohama, Japan). Insulin sensitivity was determined using homeostatic model assessment-insulin resistance (HOMA-IR). 19 The HOMA-IR index is calculated from both fasting glucose and insulin levels as follows: HOMA-IR index ¼ fasting glucose (mg dl À1 ) Â fasting insulin (mU ml À1 )/405. Mouse adiposity was assessed by computed tomography scanning (LaTheta, Hitachi, Aloka Medical, Ltd, Tokyo, Japan) as previously described. 18 Blood pressure was monitored every 4 weeks using a tail-cuff monitor (BP Monitor for Mice & Rats Model MK-2000, Muromachi Co., Ltd, Tokyo, Japan). Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), the respiratory exchange ratio (RER) and activity levels were determined (Light time; 13:00-17:00, Dark time; 1:00-5:00, air flow rate 0.50 l min À1 ) as previously described. 18 For exercise experiments, mice were allowed to adapt to an air-tight treadmill chamber (Model MK-680AT/02 M, Muromachi Co., Ltd) for 30 min (air flow rate 0.90 l min À1 ) at which point VO 2 and VCO 2 were stable; measurements were then continued for another 30 min while mice were in a sedentary state. Mice then exercised on a treadmill at a speed of 10 m min À1 , and VO 2 , VCO 2 and RER were measured for 30 min as previously described. 20 Quantitative real-time PCR Total RNA was isolated using TRIzol reagent (Invitrogen Japan KK, Tokyo, Japan). DNase-treated RNA was reverse transcribed using a PrimeScript RT reagent Kit (Takara Bio, Shiga, Japan). PCR products were analyzed with a Thermal Cycler Dice Real-Time system (Takara Bio), and relative transcript abundance was normalized to that of b-actin mRNA. Oligonucleotides used for PCR are listed in Table 1 . 
Abbreviations: Acaa1a, acetyl-CoA acyltransferase 1A; ACADL, acyl-CoA dehydrogenase, long chain; ACADM, acyl-CoA dehydrogenase, medium chain; ACADS, acyl-CoA dehydrogenase, short chain; ACOX, acyl-CoA oxidase; ACSL1, acyl-CoA synthetase long-chain family member 1; CD, cluster of differentiation; CPT1b, carnitine palmitoyl-transferase 1B; FABP, fatty acid binding protein; FATP1, fatty acid transport protein 1; MFP2, multifunctional protein 2; PGC1, proliferator-activated receptor-g coactivator -1; PPAR, peroxisome proliferator-activated receptor; UCP, uncoupling protein; VE-cadherin, vascular endothelial cadherin. 
RESULTS

Nifedipine treatment reduces adipose tissue weight and volume
After 16 weeks of nifedipine treatment (1 mg kg À1 per day), neither the systolic blood pressure (Table 2) nor the heart rate (data not shown) changed significantly in eNOS-deficient mice compared with the control mice. After 16 weeks of treatment, the overall body weight of the nifedipine-treated mice did not differ significantly from the control mice, although 16 weeks of nifedipine administration trended towards a reduction (P¼0.090, Table 2 ). Indeed, the body weight gain ratio (increased weight per mouse body weight) of nifedipine-treated mice was significantly less than the control mice (P¼0.018, Figure 1a ), suggesting that nifedipine treatment antagonizes body weight increases. Significant reductions in the weight of epididymal WAT and brown adipose tissue proportional to body weight were observed in nifedipine-treated mice (P¼0.0038 and P¼0.0016, respectively, Figure 1b ), whereas the skeletal muscle weight relative to body weight Figures 1c and d) , whereas the lean body weight remained unchanged (Figure 1e ). Moreover, significant reductions in both visceral adipose and subcutaneous adipose volume per body weight were observed in nifedipine-treated mice (P¼0.017 and P¼0.047, respectively, Figures 1f and 1g, respectively) . Taken together, these results indicate that nifedipine treatment antagonizes increases in body fat mass.
Nifedipine treatment enhances oxygen expenditure and reduces the RER To investigate the mechanism by which nifedipine promotes WAT mass reduction, we analyzed basal metabolic rate, locomotor activity and food intake in eNOS-deficient mice (Figure 2 ). Nifedipine-treated mice exhibited a significant increase in whole-body VO 2 rates in darktime measurements (P¼0.027, Figure 2a ) relative to control mice, whereas no significant changes were observed in VCO 2 rates (Figure 2b) . Furthermore, the RER (VCO 2 /VO 2 ) of nifedipine-treated mice was significantly decreased in dark time, suggesting a greater fat utilization as an energy source (P¼0.025, Figure 2c ). Nifedipinetreated mice exhibited a significant increase in locomotor activity compared with control mice, particularly in dark time (P¼0.044, Figure 2d ). No significant change was observed in food intake per body weight (Figure 2e ) or rectal temperature (data not shown). Taken together, these results suggest that nifedipine treatment increases energy expenditure. We further investigated whether nifedipine treatment alters the oxygen consumption and carbon dioxide production during treadmill-induced exercise (Figure 3 ). To accomplish this, we monitored VO 2 , VCO 2 and RER during 10 m min À1 treadmill running. Although no significant change was observed in VO 2 (Figure 3a) , the VCO 2 of the nifedipine-treated mice was significantly decreased (25-30 min exercise; P¼0.013, Figure 3b ) compared to controls. Interestingly, after 10 min of exercise, the RER of Figure 3c ). These results agree with a spontaneous activity analysis showing reduced RER in nifedipine-treated mice (see Figure 2c ). We also investigated the effect of nifedipine treatment on exercise tolerance (Supplementary Figure S1 ) and observed no significant change in endurance capacity compared with control mice. Overall, our findings suggest that nifedipine treatment increases lipid utilization rather than carbohydrates as an energy source during both spontaneous and treadmill-induced exercise, likely leading to decreased fat tissue weight.
Nifedipine treatment increases PGC-1a mRNA levels and b-oxidation in skeletal muscle To determine the molecular basis for metabolic changes seen in nifedipine-treated mice, we undertook quantitative real-time PCR analysis to examine mRNA levels of factors regulating energy expenditure and metabolic activity in skeletal muscle using eNOS-deficient mice (Figure 4 ). PGC-1a expression was significantly increased in the soleus muscle of nifedipine-treated mice (P¼0.0051, Figure 4 ). The expression of fatty acid transport protein 1 and acyl-coenzyme A oxidase 1, a peroxisomal b-oxidation-related gene, was significantly increased in nifedipine-treated mice compared with control mice (P¼0.016 and P¼0.008, respectively, Figure 4 ), suggesting that nifedipine-induced PGC-1a in skeletal muscle may activate fat utilization by enhancing fatty acid transport and b-oxidation. Expression levels of blood vascular markers, including CD31, Tie2 and VE-cadherin, in the soleus muscle were equivalent in nifedipine-treated and untreated mice, suggesting that non-hypotensive drug doses do not induce blood vessel formation in skeletal muscle (data not shown).
Nifedipine treatment increases insulin sensitivity
It has recently been reported that nifedipine administration significantly suppresses serum insulin levels in KK-A y mice, suggesting that nifedipine treatment improves hyperinsulinemia. 17 Therefore, we investigated whether serum insulin or glucose levels would be altered by nifedipine treatment at the dosages outlined in the Methods section. Although nifedipine-treated mice exhibited no change in serum glucose levels, they did show lower serum insulin levels than control mice both after fasting and under ad libitum feeding conditions (P¼0.024 and P¼0.0032, respectively, Figure 5a ). The HOMA-IR index was also significantly lower in nifedipine-treated mice (P¼0.030, Figure 5b ) than in control mice. These results indicate that nifedipine treatment promotes greater insulin sensitivity.
To confirm this finding, we conducted ITT and GTT tolerance tests, and found a tendency toward increased insulin sensitivity in nifedipine-treated mice (P¼0.089, Figures 5c and d) . Serum glucose levels after glucose injection were significantly improved in nifedipinetreated mice compared with control mice (P¼0.021 and P¼0.024, respectively, Figures 5e and f) . These results suggest that the attenuation of hyperinsulinemia by nifedipine treatment may contribute to its beneficial effects on energy expenditure.
DISCUSSION
In this study, we demonstrated that long-term treatment with nonhypotensive doses of nifedipine enhances whole-body energy expenditure by increasing oxygen consumption, resulting in reduced body fat gain in mildly obese mice. In a clinical trial, Tuck et al. 15 showed a significant decrease in body weight after nifedipine treatment (30-180 mg per day orally for 3 months) in patient groups classified as obese (BMI430) or overweight (25pBMIp30) with mild-to-moderate hypertension, whereas patients of normal weight (BMIo25) did not show decreases in body weight. By contrast, nifedipine reduced blood pressure equally well in all hypertensive patient groups. Radin et al. 16 also reported that nifedipine treatment (average dose 114 mg kg À1 per day in rat chow for 3 months) decreased body weight and abdominal and subcutaneous fat masses of SHHF/Mcc-fa cp /fa cp rats, which are a spontaneous rat model of hypertension, obesity, insulin resistance, glucose intolerance and hyperlipidemia. These reports indicate that antihypertensive doses of nifedipine treatment can decrease body weight in obese hypertensive subjects. However, it is possible that nifedipine's activity as a vasodilator at these doses promotes blood flow into skeletal muscle and enhances the fatty acid supply as an energy source to these tissues. Therefore, we investigated whether nifedipine treatment directly suppresses body weight without an antihypertensive effect. The present study revealed that nonhypotensive doses of nifedipine (a dose of 1 mg kg À1 per day via infusion pump for 4 months) significantly reduced epididymal WAT and body weight gain, suggesting that the nifedipine has an antiobesity effect. In agreement, Russell et al. 21, 22 reported that nifedipine treatment (a dose of 15 mg kg À1 per day in food pellets for 7.5 months) moderately decreased the body weight of JCR:LA-cp/cp rats, a normotensive obese rat model with marked hyperlipidemia and insulin resistance, indicating that nifedipine directly affects weight loss. Iwai et al. 17 also reported that non-hypotensive doses of nifedipine (average dose 1.5 mg kg À1 per day in lab chow for 5 weeks) significantly decreased epididymal WAT weight and moderately decreased wholebody weight of obese diabetic KK-A y mice by stimulating adipocyte differentiation. This observation strongly suggests that non-hypotensive doses of nifedipine treatment enhance fat metabolism. The dihydropyridine receptor, a target of nifedipine, is expressed in skeletal muscle cells 23 although its function in those tissues remains unknown. A previous study reported that nifedipine treatment increases fatty acid oxidation in C2C12 myotubes. 24 Thus, nifedipine may directly inhibit the dihydropyridine receptor expressed in skeletal Nifedipine increases energy expenditure Z Tian et al muscle cells and may contribute to increased energy expenditure and fatty acid oxidation, although the detailed mechanism by which nonhypotensive doses of nifedipine impact obese subjects remains unclear. Another dihydropyridine Ca antagonist, benidipine hydrochloride, an L-type Ca channel blocker, reportedly reduces blood pressure and inhibits weight gain in rats and dogs. 25, 26 Benidipine treatment also seemingly decreases body weight and body fat in obese mice models after pretreatment with monosodium-L-glutamate. 27 However, only nifedipine and benidipine have been reported to have anti-obesity effects among Ca channel blockers. Therefore, the anti-obesity effect of both the drugs may be unique to these Ca channel blockers.
Peroxisomal b-oxidation reportedly functions in thermogenesis, because the first oxidation step catalyzed by fatty acyl-CoA oxidase is not coupled to ATP production, and thus energy is released as heat. 28 In this study, we found that PGC-1a and acyl-coenzyme A oxidase 1 expression levels were increased by nifedipine treatment.
It has recently been reported that PGC-1a regulates factors required for peroxisomal b-oxidation, such as acyl-coenzyme A oxidase 1. 29 Therefore, nifedipine may exert an anti-obesity effect by upregulating PGC-1a, thus increasing thermogenesis mediated by acyl-coenzyme A oxidase 1 in skeletal muscle. In addition, we also observed fatty acid transport protein 1 upregulation in skeletal muscle of nifedipinetreated mice, suggesting that nifedipine enhances fatty acid transport into skeletal muscle cells.
Recently, studies have suggested that nifedipine pleiotropically activates the eNOS pathway. 7, 30 Indeed, Iwai et al. 17 reported that nifedipine treatment reduced superoxide levels by increasing eNOS activity. However, in our study of eNOS-deficient mice, we found that the nifedipine has eNOS-independent effects on increasing the energy expenditure in skeletal muscle and insulin sensitivity. Thus, it remains unclear whether nifedipine-induced eNOS upregulation is a major pathway for countering obesity and improving insulin resistance. Finally, we found that nifedipine treatment enhances energy expenditure by increasing PGC-1a expression in skeletal muscle. However, it is unclear whether nifedipine-induced PGC-1a upregulation has a direct effect on insulin sensitivity. Previous studies have reported that expression of PGC-1a is upregulated by prolonged exercise in rats 31 and that moderate PGC-1a overexpression in rat skeletal muscle in vivo improves insulin sensitivity. 32 Future investigations could address whether prolonged exercise combined with nifedipine treatment could synergistically elevate PGC-1a mRNA levels and improve insulin sensitivity in patients with obesity and/or type 2 diabetes.
